| Bioactivity | Olvanil (NE-19550) is an analgesic and an agonist of transient receptor potential vanilloid type 1 (TRPV1) channels with an EC50 of 0.7 nM[1]. |
| Invitro | Olvanil affects C6 glioma cell proliferation (IC50 value of 5.5 μM)[2] |
| In Vivo | Olvanil is one capsaicin analog, which acts as an agonist at the vanilloid receptor. Olvanil may have causes an anxiogenic-like effect. Doses of 0, 0.2, 1.0 and 5.0 mg/kg Olvanil, respectively, yielded percent open arm entries at 5 min of 25±10.1, 19.3±7.1, 14.9±5.9 and 0±0[3]. Animal Model: |
| Name | Olvanil |
| CAS | 58493-49-5 |
| Formula | C26H43NO3 |
| Molar Mass | 417.62 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
| Reference | [1]. Giovanni Appendino, et al. Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential. J Pharmacol Exp Ther. 2005 Feb;312(2):561-70. [2]. S O Jacobsson, et al. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors.J Pharmacol Exp Ther. 2001 Dec;299(3):951-9. [3]. John W Kasckow, et al. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):291-5. |